Literature DB >> 24486140

An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells.

Janet Kerstin Peper1, Heiko Schuster2, Markus W Löffler3, Barbara Schmid-Horch4, Hans-Georg Rammensee5, Stefan Stevanović6.   

Abstract

The in vitro assessment of T-cell-mediated cytotoxicity plays an important and increasingly relevant role both in preclinical target evaluation and during immunomonitoring to accompany clinical trials employing targeted immunotherapies. For a long time, the gold standard for this purpose has been the chromium release assay (CRA). This end point assay, however, shows several disadvantages including the inevitable use of radioactivity. Based on electrical impedance measurements (using the xCELLigence system), we have established a label-free assay, facilitating the real-time monitoring of T-cell-mediated cytotoxicity. The coculture of peptide-specific T-cell lines with peptide-loaded target cells reproducibly led to a decrease in impedance due to induced apoptosis and detachment of target cells. Comparing our results to the standard CRA assay, we could demonstrate that impedance-based measurements show comparable results after short incubation periods (6h) but outperform the CRA both in reproducibility and sensitivity after prolonged incubation (24h), enabling the detection of target cell lysis with an effector to target ratio as low as 0.05:1. The impedance-based assay represents a valuable and highly sensitive tool for label-free real-time high throughput analysis of T-cell-mediated cytotoxicity.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chromium release assay; Impedance; Real time; T-cell cytotoxicity assay; xCELLigence

Mesh:

Substances:

Year:  2014        PMID: 24486140     DOI: 10.1016/j.jim.2014.01.012

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  26 in total

1.  A high-performance, non-radioactive potency assay for measuring cytotoxicity: A full substitute of the chromium-release assay targeting the regulatory-compliance objective.

Authors:  Alexis Rossignol; Véronique Bonnaudet; Béatrice Clémenceau; Henri Vié; Laurent Bretaudeau
Journal:  MAbs       Date:  2017-02-08       Impact factor: 5.857

2.  Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients.

Authors:  P Schlegel; T Feuchtinger; C Nitschke-Gérard; U J Eva Seidel; A-M Lang; C Kyzirakos; H-M Teltschik; M Ebinger; M Schumm; E Koscielniak; R Handgretinger; P Lang
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

3.  Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy.

Authors:  Yismeilin R Feliz-Mosquea; Ashley A Christensen; Adam S Wilson; Brian Westwood; Jasmina Varagic; Giselle C Meléndez; Anthony L Schwartz; Qing-Rong Chen; Lesley Mathews Griner; Rajarshi Guha; Craig J Thomas; Marc Ferrer; Maria J Merino; Katherine L Cook; David D Roberts; David R Soto-Pantoja
Journal:  Breast Cancer Res Treat       Date:  2018-07-28       Impact factor: 4.872

4.  Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Authors:  Benjamin Y Jin; Tracy E Campbell; Lindsey M Draper; Sanja Stevanović; Bianca Weissbrich; Zhiya Yu; Nicholas P Restifo; Steven A Rosenberg; Cornelia L Trimble; Christian S Hinrichs
Journal:  JCI Insight       Date:  2018-04-19

5.  CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.

Authors:  David R Soto-Pantoja; Masaki Terabe; Arunima Ghosh; Lisa A Ridnour; William G DeGraff; David A Wink; Jay A Berzofsky; David D Roberts
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

6.  A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells.

Authors:  Andrew G MacLean; Edith Walker; Gautam K Sahu; Gail Skowron; Preston Marx; Dorothee von Laer; Richard P Junghans; Stephen E Braun
Journal:  J Med Primatol       Date:  2014-08-20       Impact factor: 0.667

Review 7.  Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity.

Authors:  Stefan Kiesgen; John C Messinger; Navin K Chintala; Zachary Tano; Prasad S Adusumilli
Journal:  Nat Protoc       Date:  2021-02-15       Impact factor: 13.491

8.  Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.

Authors:  Joseph P Antonios; Horacio Soto; Richard G Everson; Diana Moughon; Joey R Orpilla; Namjo P Shin; Shaina Sedighim; Janet Treger; Sylvia Odesa; Alexander Tucker; William H Yong; Gang Li; Timothy F Cloughesy; Linda M Liau; Robert M Prins
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

9.  Enhanced activation of human NK cells by drug-exposed hepatocytes.

Authors:  Frank Fasbender; Martin Obholzer; Sarah Metzler; Regina Stöber; Jan G Hengstler; Carsten Watzl
Journal:  Arch Toxicol       Date:  2020-02-14       Impact factor: 5.153

10.  A versatile flow-based assay for immunocyte-mediated cytotoxicity.

Authors:  Peter M Rabinovich; Jialing Zhang; Samuel R Kerr; Bao-Hui Cheng; Marina Komarovskaya; Alexey Bersenev; Michael E Hurwitz; Diane S Krause; Sherman M Weissman; Samuel G Katz
Journal:  J Immunol Methods       Date:  2019-09-13       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.